Arrowhead (ARWR) is down -8.9%, or -$1.49 to $15.28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Cautious Hold Rating on Arrowhead Pharmaceuticals Amid Uncertainty in Sarepta Partnership
- Arrowhead Pharmaceuticals Advances Phase 3 Study of Zodasiran for Cholesterol Management
- Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Hypertriglyceridemia
- Arrowhead doses first patient in YOSEMITE trial
- Arrowhead completes enrollment in SHASTA-3, SHASTA-4 and MUIR-3